Pharmacokinetics of a Standard Dose of Cytarabine in a Patient with Acute Promyelocytic Leukemia Undergoing Continuous A
- PDF / 64,400 Bytes
- 3 Pages / 612 x 792 pts (letter) Page_size
- 68 Downloads / 191 Views
HEMATOLOGY Letter to the Editor
Pharmacokinetics of a Standard Dose of Cytarabine in a Patient with Acute Promyelocytic Leukemia Undergoing Continuous Ambulatory Peritoneal Dialysis Makoto Takeuchi,a Takahiro Yamauchi,b Isao Yoshida,a Ryo Soda,a Takanori Ueda,b Kiyoshi Takahashia a
Department of Internal Medicine, National Minami Okayama Hospital, Okayama; b First Department of Internal Medicine, Fukui Medical University, Fukui, Japan
Received August 21, 2002; received in revised form November 5, 2002; accepted November 15, 2002
Int J Hematol. 2003;77:196-198. ©2003 The Japanese Society of Hematology
for 3 days and cytarabine (200 mg/m2) by continuous infusion for 5 days. At that time, the patient underwent 4 CAPD exchanges with 1.5 L of dialysate containing 2.5% glucose, and almost no urine output was noted. Duration of myelosuppression with this regimen was 10 days for neutrophils (
Data Loading...
